Villere ST Denis J & Co. LLC Trims Position in Teleflex Incorporated (NYSE:TFX)

Villere ST Denis J & Co. LLC decreased its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 21.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 136,980 shares of the medical technology company’s stock after selling 37,878 shares during the period. Teleflex accounts for about 2.8% of Villere ST Denis J & Co. LLC’s portfolio, making the stock its 13th largest position. Villere ST Denis J & Co. LLC’s holdings in Teleflex were worth $33,878,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Cromwell Holdings LLC increased its position in Teleflex by 59.0% during the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 49 shares during the period. Canada Pension Plan Investment Board purchased a new position in Teleflex during the 2nd quarter valued at about $42,000. GAMMA Investing LLC increased its position in Teleflex by 131.1% during the 3rd quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company’s stock valued at $42,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc increased its position in Teleflex by 20,700.0% during the 2nd quarter. Versant Capital Management Inc now owns 208 shares of the medical technology company’s stock valued at $44,000 after purchasing an additional 207 shares during the period. Finally, Blue Trust Inc. increased its position in Teleflex by 78.2% during the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical technology company’s stock valued at $48,000 after purchasing an additional 93 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Down 1.3 %

TFX stock opened at $195.53 on Friday. The firm has a 50 day moving average of $235.39 and a 200 day moving average of $223.70. The stock has a market capitalization of $9.08 billion, a PE ratio of 38.87, a price-to-earnings-growth ratio of 2.07 and a beta of 1.18. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. Teleflex Incorporated has a 52 week low of $194.58 and a 52 week high of $257.85.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.38 by $0.11. The company had revenue of $764.40 million during the quarter, compared to analysts’ expectations of $768.68 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. Teleflex’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period last year, the business earned $3.64 EPS. Sell-side analysts forecast that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Friday, November 15th. Teleflex’s payout ratio is 27.04%.

Insider Buying and Selling at Teleflex

In other Teleflex news, Director Stuart A. Randle sold 2,674 shares of Teleflex stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the completion of the sale, the director now directly owns 5,496 shares in the company, valued at approximately $1,313,159.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.43% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Truist Financial reissued a “hold” rating and set a $227.00 target price (down previously from $255.00) on shares of Teleflex in a research report on Monday, November 4th. Stephens raised their price target on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Mizuho lowered their price target on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a report on Friday, November 1st. Finally, Royal Bank of Canada lowered their price target on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $259.25.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.